FDA seeks more safety data for Injectafer
Executive Summary
Luitpold received a "not approvable" letter from FDA for the iron deficiency anemia drug Injectafer (ferric carboxymaltose), the firm reports March 12. The agency requests additional clinical trials to provide more data about a signal that led the Drug Safety and Risk Management Advisory Committee to vote 12-2 that Injectafer has a mortality disadvantage compared to oral iron (1"The Pink Sheet" Feb. 11, 2008, p. 28). Luitpold is working on new studies to support the application, CEO Mary Jane Helenek says